Subrata Kumar Ghosh

Subrata Kumar Ghosh

Auto-generated profile, based on publicly available information

Subrata Kumar Ghosh

Department of Chemistry, Texas A&M University , P.O. Box 30012, College Station, Texas 77842-3012, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2016 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
AEAndreas Ehnbom
Andreas Ehnbom
SGSubrata K. Ghosh
Subrata K. Ghosh
KLKyle G. Lewis
Kyle G. Lewis
JGJohn A. Gladysz
John A. Gladysz
The title compounds exhibit metal centered chirality (Λ/Δ), chelate conformers (λ/δ), configurational diastereomers (R/S) due to carbon stereocenters, geometric isomers (fac/mer), and C–C bond/C3axis alignment modes (lel/ob).

23 March 2015 in ACS Central Science
Verified
Journal Article
Open access
KLKyle G. Lewis
Kyle G. Lewis
SGSubrata K. Ghosh
Subrata K. Ghosh
NBNattamai Bhuvanesh
Nattamai Bhuvanesh
JGJohn A. Gladysz
John A. Gladysz
In the quest for new catalysts that can deliver single enantiomer pharmaceuticals and agricultural chemicals, chemists have extensively mined the “chiral pool”, with little in the way of inexpensive, readily available building blocks now remaining. It is found that Werner complexes based upon the D3 symmetric chiral trication [Co(en)3]3+ (en = 1,2-ethylenediamine), which features an earth abundant metal and cheap ligand type, and was among the first inorganic compounds resolved into enantiomers 103 years ago, catalyze a valuable carbon–carbon bond forming reaction, the Michael addition of malonate esters to nitroalkenes, in high enantioselectivities and without requiring inert atmosphere conditions. The title catalysts, [Co((S,S)-dpen)3]3+ ((S,S)-33+) 3X–, employ a commercially available chiral ligand, (S,S)-1,2-diphenylethylenediamine. The rates and ee values are functions of the configuration of the cobalt center (Λ/Δ) and the counteranions, which must be lipophilic to solubilize the trication in nonaqueous media. The highest enantioselectivities are obtained with Λ and 2Cl–BArf–, 2BF4–BArf–, or 3BF4– salts (BArf– = B(3,5-C6H3(CF3)2)4–). The substrates are not activated by metal coordination, but rather by second coordination sphere hydrogen bonding involving the ligating NH2 groups. Crystal structures and NMR data indicate enthalpically stronger interactions with the NH moieties related by the C3 symmetry axis, as opposed to those related by the C2 symmetry axes; rate trends and other observations suggest this to be the catalytically active site. Both Λ- and Δ-(S,S)-33+ 2Cl–BArf– are effective catalysts for additions of β-ketoesters to RO2CN═NCO2R species (99–86% yields, 81–76% ee), which provide carbon–nitrogen bonds and valuable precursors to α-amino acids.

15 May 2024 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Open access
Marietta IacucciMarietta Iacucci
Marietta Iacucci
Giovanni SantacroceGiovanni Santacroce
Giovanni Santacroce
IZIrene Zammarchi
Irene Zammarchi
YMYasuharu Maeda
Yasuharu Maeda
RARocio del Amor
Rocio del Amor
SGSubrata Ghosh
Subrata Ghosh
Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.


25 February 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
SGSubrata K. Ghosh
Subrata K. Ghosh
CGCarola Ganzmann
Carola Ganzmann
NBNattamai Bhuvanesh
Nattamai Bhuvanesh
JGJohn A. Gladysz
John A. Gladysz

4 October 2010 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
SGSubrata K. Ghosh
Subrata K. Ghosh
ZZZilong Zheng
Zilong Zheng
BNBukuo Ni
Bukuo Ni